Literature DB >> 29886044

APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Pazit Beckerman1, Katalin Susztak2.   

Abstract

Chronic kidney disease (CKD) affects millions of people and constitutes a major health and financial burden worldwide. People of African descent are at an increased risk of developing kidney disease, which is mostly explained by two variants in the Apolipoprotein L1 (APOL1) gene that are found only in people of west African origin. It is hypothesized that these variants were genetically selected due to the protection they afford against African sleeping sickness, caused by the parasite Trypanosoma brucei. Targeting mutant APOL1 could have substantial therapeutic potential for treating kidney disease. In this review, we will describe the intriguing interplay between microbiology, genetics, and kidney disease as revealed in APOL1-associated kidney disease, discuss APOL1-induced cytotoxicity and its therapeutic implications.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apolipoprotein 1; chronic kidney disease; genetics

Mesh：

Substances：

Year:  2018        PMID： 29886044      PMCID： PMC6101980          DOI： 10.1016/j.molmed.2018.05.008

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  103 in total

Review 1.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

2.  Apolipoprotein L1-associated nephropathy and the future of renal diagnostics.

Authors:  Christopher P Larsen; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2015-01-08       Impact factor: 10.121

3.  Membrane dynamics: How lysosomes SNARE autophagosomes.

Authors:  Kirsty Minton
Journal:  Nat Rev Mol Cell Biol       Date:  2012-12-19       Impact factor: 94.444

4.  Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.

Authors:  Gilad Doitsh; Nicole L K Galloway; Xin Geng; Zhiyuan Yang; Kathryn M Monroe; Orlando Zepeda; Peter W Hunt; Hiroyu Hatano; Stefanie Sowinski; Isa Muñoz-Arias; Warner C Greene
Journal:  Nature       Date:  2014-01-23       Impact factor: 49.962

5.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

6.  Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene.

Authors:  P N Duchateau; C R Pullinger; M H Cho; C Eng; J P Kane
Journal:  J Lipid Res       Date:  2001-04       Impact factor: 5.922

7.  Patterns of Kidney Function Decline Associated with APOL1 Genotypes: Results from AASK.

Authors:  Adrienne Tin; Morgan E Grams; Michelle Estrella; Michael Lipkowitz; Tom H Greene; Wen Hong Linda Kao; Liang Li; Lawrence J Appel
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-26       Impact factor: 8.237

Review 8.  The Cell Biology of APOL1.

Authors:  John F O'Toole; Leslie A Bruggeman; Sethu Madhavan; John R Sedor
Journal:  Semin Nephrol       Date:  2017-11       Impact factor: 5.299

Review 9.  Apolipoprotein L1 and Kidney Disease in African Americans.

Authors:  David J Friedman; Martin R Pollak
Journal:  Trends Endocrinol Metab       Date:  2016-03-03       Impact factor: 12.015

10.  ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death.

Authors:  Siqin Zhaorigetu; Guanghua Wan; Ramesh Kaini; Zeyu Jiang; Chien-an A Hu
Journal:  Autophagy       Date:  2008-11-23       Impact factor: 16.016
View more
  13 in total

1.  APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.

Authors:  Adriana M Hung; Shailja C Shah; Alexander G Bick; Zhihong Yu; Hua-Chang Chen; Christine M Hunt; Frank Wendt; Otis Wilson; Robert A Greevy; Cecilia P Chung; Ayako Suzuki; Yuk-Lam Ho; Elvis Akwo; Renato Polimanti; Jin Zhou; Peter Reaven; Philip S Tsao; J Michael Gaziano; Jennifer E Huffman; Jacob Joseph; Shiuh-Wen Luoh; Sudha Iyengar; Kyong-Mi Chang; Juan P Casas; Michael E Matheny; Christopher J O'Donnell; Kelly Cho; Ran Tao; Katalin Susztak; Cassianne Robinson-Cohen; Sony Tuteja; Edward D Siew
Journal:  JAMA Intern Med       Date:  2022-04-01       Impact factor: 21.873

2.  The key role of NLRP3 and STING in APOL1-associated podocytopathy.

Authors:  Junnan Wu; Archana Raman; Nathan J Coffey; Xin Sheng; Joseph Wahba; Matthew J Seasock; Ziyuan Ma; Pazit Beckerman; Dorottya Laczkó; Matthew B Palmer; Jeffrey B Kopp; Jay J Kuo; Steven S Pullen; Carine M Boustany-Kari; Andreas Linkermann; Katalin Susztak
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

3.  Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.

Authors:  Ya-Wen Yang; Bibek Poudel; Julia Frederick; Poonam Dhillon; Rojesh Shrestha; Ziyuan Ma; Junnan Wu; Koji Okamoto; Jeffrey B Kopp; Sheri L Booten; Danielle Gattis; Andrew T Watt; Matthew Palmer; Mariam Aghajan; Katalin Susztak
Journal:  Mol Ther       Date:  2022-04-20       Impact factor: 12.910

Review 4.  Podocytopathies.

Authors:  Jeffrey B Kopp; Hans-Joachim Anders; Katalin Susztak; Manuel A Podestà; Giuseppe Remuzzi; Friedhelm Hildebrandt; Paola Romagnani
Journal:  Nat Rev Dis Primers       Date:  2020-08-13       Impact factor: 52.329

5.  APOL1 at 10 years: progress and next steps.

Authors:  Barry I Freedman; Jeffrey B Kopp; Matthew G Sampson; Katalin Susztak
Journal:  Kidney Int       Date:  2021-03-29       Impact factor: 18.998

Review 6.  Podocyte Injury in Lupus Nephritis.

Authors:  Hamza Sakhi; Anissa Moktefi; Khedidja Bouachi; Vincent Audard; Carole Hénique; Philippe Remy; Mario Ollero; Khalil El Karoui
Journal:  J Clin Med       Date:  2019-08-29       Impact factor: 4.241

7.  APOL1 Risk Genotypes Are Associated With Early Kidney Damage in Children in Sub-Saharan Africa.

Authors:  Pepe M Ekulu; Agathe B Nkoy; Dieumerci K Betukumesu; Michel N Aloni; Jean Robert R Makulo; Ernest K Sumaili; Eric M Mafuta; Mohamed A Elmonem; Fanny O Arcolino; Faustin N Kitetele; François B Lepira; Lambertus P van den Heuvel; Elena N Levtchenko
Journal:  Kidney Int Rep       Date:  2019-04-11

8.  Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.

Authors:  Archna Bajaj; Andrea Ihegword; Chengxiang Qiu; Aeron M Small; Wei-Qi Wei; Lisa Bastarache; QiPing Feng; Rachel L Kember; Marjorie Risman; Roy D Bloom; David L Birtwell; Heather Williams; Christian M Shaffer; Jinbo Chen; Regeneron Genetics Center; Joshua C Denny; Daniel J Rader; C Michael Stein; Scott M Damrauer; Katalin Susztak
Journal:  Kidney Int       Date:  2020-02-17       Impact factor: 10.612

9.  Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis.

Authors:  Marius A Øvrehus; Tine S Oldereid; Aydin Dadfar; Rune Bjørneklett; Knut I Aasarød; Agnes B Fogo; Joachim H Ix; Stein I Hallan
Journal:  Kidney Int Rep       Date:  2019-12-27

10.  APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin.

Authors:  Sophie Uzureau; Laurence Lecordier; Pierrick Uzureau; Dorle Hennig; Jonas H Graversen; Fabrice Homblé; Pepe Ekulu Mfutu; Fanny Oliveira Arcolino; Ana Raquel Ramos; Rita M La Rovere; Tomas Luyten; Marjorie Vermeersch; Patricia Tebabi; Marc Dieu; Bart Cuypers; Stijn Deborggraeve; Marion Rabant; Christophe Legendre; Søren K Moestrup; Elena Levtchenko; Geert Bultynck; Christophe Erneux; David Pérez-Morga; Etienne Pays
Journal:  Cell Rep       Date:  2020-03-17       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.